Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats.
Drug Des Devel Ther
; 13: 3929-3937, 2019.
Article
em En
| MEDLINE
| ID: mdl-31819367
ABSTRACT
OBJECTIVE:
To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60 tween 80 (7030%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS ANDMETHODS:
A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally.RESULTS:
We found decreased Tmax, increased Cmax, AUC0-6, AUC0-∞ and ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan.CONCLUSION:
Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Triptaminas
/
Oxazolidinonas
/
Agonistas do Receptor 5-HT1 de Serotonina
/
Transtornos de Enxaqueca
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article